Deep-vein thrombosis

Lancet

Volumn 353, Issue 9151, 1999, Pages 479-485

  Lensing, Anthonie W A ^a   Prandoni, Paolo ^b   Prins, Martin H ^a   Büller, H R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; ECHOGRAPHY; GENETIC DISORDER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; PHLEBOGRAPHY; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RECURRENT DISEASE; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURGICAL STOCKING; THROMBECTOMY; THROMBOEMBOLISM; VEIN SURGERY; VENA CAVA FILTER;

EID: 0033528247     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04298-6     Document Type: Review

References (48)

1. Salzman E.W., Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis: basic principles and clinical practice. 1993;1275-1298 JB Lippincott, Philadelphia.
2. Carson J.L., Kelley M.A., Duff A.et al. The clinical course of pulmonary embolism. N Engl J Med. 326:1992;1240-1245.
3. Prandoni P., Lensing A.W.A., Cogo A.et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 125:1996;1-7.
4. Nordström M., Lindbläaed B., Bergqvist D., Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 232:1992;155-160.
5. Hansson P.O., Werlin L., Tibblin G., Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med. 157:1997;1665-1670.
6. Cohen A.T., Edmondson R.A., Phillips M.J., Ward V.P., Kakkar V.V. The changing pattern of venous thromboembolic disease. Haemostasis. 26:1996;65-71.
7. Triplett D.A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Throm Res. 78:1995;1-31.
8. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 346:1995;1575-1582.
9. Hirsh J., Prins M.H., Samama M. Approach to the thrombophilic patient for hemostasis and thrombosis: basic princples and clinical practice. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis: basic principles and clinical practice. 1993;1543-1561 JB Lippincott, Philadelphia.
10. Heijboer H., Brandjes D.P.M., Büller H.R., Sturk A., ten Cate J.W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 323:1990;1512-1515.
11. Bertina R.M., Koeleman B.P.C., Koster T.et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
12. 506→Gln mutation in the gene for factor V. N Engl J Med. 336:1997;399-403.
13. den Heijer M., Blom H.J., Gerrits W.B.et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 345:1995;882-885.
14. den Heijer M., Koster T., Blom H.J.et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 334:1996;759-762.
15. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3689-3703.
16. Koster T., Blann A.D., Briët E., Vandenbroucke J.P., Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 345:1995;152-155.
17. Lensing A.W.A., Hirsh J., Büller H.R. Diagnosis of venous thrombosis. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis: basic principles and clinical practice. 1993;1297-1321 JB Lippincott, Phildelphia.
18. Lensing A.W.A., Prandoni P., Brandjes D.et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med. 320:1989;342-345.
19. Davidson B.L., Deppert E.J. Ultrasound for the diagnosis of deep vein thrombosis: where to now? BMJ. 316:1998;2-3.
20. Hull R., Hirsh J., Sackett D.L.et al. Replacement of venography in suspected venous thrombosis by impedance plethysmography and 125I-fibrinogen leg scanning: a less invasive approach. Ann Intern Med. 94:1981;12-15.
21. Kraaijenhagen R.A., Lensing A.W.A., Lijmer J.G.et al. Diagnostic strategies for the management of patients with clinically suspected deep vein thrombosis. Curr Opin Pulm Med. 3:1997;268-274.
22. Cogo A., Lensing A.W.A., Koopman M.M.W.et al. Simplified compression ultrasound strategy for the diagnostic management of patients with clinically suspected venous thrombosis. BMJ. 316:1998;17-20.
23. Birdwell B., Raskob G., Whitsett T.et al. Clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 128:1998;1-7.
24. Hull R., Hirsh J., Sackett D.L.et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation. 64:1981;622-625.
25. Wells P.S., Anderson D.R., Bormanis J.et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 350:1997;1795-1798.
26. Hull R.D., Carter C.J., Jay R.M.et al. The diagnosis of acute recurrent DVT: a diagnostic challenge. Circulation. 67:1983;901-906.
27. Huisman M.V., Büller H.R., ten Cate J.W. Utility of impedance plethysmography in the diagnosis of recurrent DVT. Arch Intern Med. 148:1988;681-683.
28. Prandoni P., Cogo A., Bernardi E.et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation. 88:1993;1730-1735.
29. Hirsh J., Salzman E.W., Marder V.J. Treatment of venous thromboembolism. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis: basic principles and clinical practice. 1993;1346-1366 JB Lippincott, Philadelphia.
30. Hirsh J. Heparin N Engl J Med. 324:1991;1565-1574.
31. Weitz J.L.Low-molecular-weight heparin N Engl J Med. 337:1997;688-698.
32. Nurmohamed M.T., Rosendaal F.R., Büller H.R.et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 340:1992;152-156.
33. Lensing A.W.A., Prins M.H., Davidson B.L., Hirsh J. Low molecular weight heparin for the treatment of deep-vein thrombosis: a meta-analysis. Arch Intern Med. 155:1995;601-607.
34. Van den Belt AGM, Prins MH, Lensing AWA et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. In: The Cochrane Library [CDROM and online]: Issue 2. Oxford: Update Software, 1998.
35. Koopman M.M.W., Prandoni P., Piovella F.et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 334:1996;682-687.
36. Fiessinger J.N., Lopez-Fernandez M., Gatterer E.et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 76:1996;195-199.
37. Warkentin T.E., Levine M.N., Hirsh J.et al. Heparin-induced thrombocytopenia in patient treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
38. Greenfield L.J., Michina B.A. Twelve-year clinical experience with the Greenfield vena cava filter. Surgery. 104:1988;706-712.
39. Decousus H., Leizorovics A., Parent F.et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 338:1998;409-415.
40. Mahorner H., Castelberry J.W., Coleman W.D. Attempts to restore function in major veins which are the site of massive thombosis. Ann Surg. 146:1957;510-517.
41. Karp R.B., Wylie E.J. Recurrent thrombosis after iliofemoral venous thrombectomy. Surg Forum. 17:1966;147-153.
42. Lensing A.W.A., Hirsh J. Rationale and results of thrombolytic therapy for deep vein thrombosis. Berstein E.F. Vascular diagnosis, 4th edn. 1993;875-879 Mosby, St Louis.
43. Schulman S., Rhedin A.-S., Lindmarker P.et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 332:1995;1661-1665.
44. Prandoni P., Lensing A.W.A., Büller H.R.et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 27:1992;1128-1133.
45. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 340:1992;873-876.
46. Levine M.N., Hirsh J., Gent M.et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 74:1995;606-611.
47. Schulman S., Granqvist S., Holmstrom M.et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 336:1997;393-398.
48. Brandjes D.P.M., Büller H.R., Heijboer H.et al. Randomised trial of the effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 349:1997;759-762.